Corticosteroids and aldose reductase inhibitor Epalrestat modulates cardiac action potential via Kvβ1.1 (AKR6A8) subunit of voltage-gated potassium channel
暂无分享,去创建一个
S. Tipparaju | Feng Cheng | S. Badole | R. Kukreja | J. Tur | Aparoop Das
[1] J. Cuevas,et al. Kvβ1.1 (AKR6A8) senses pyridine nucleotide changes in the mouse heart and modulates cardiac electrical activity. , 2017, American journal of physiology. Heart and circulatory physiology.
[2] A. Bhatnagar,et al. Deletion of Kvβ1.1 subunit leads to electrical and haemodynamic changes causing cardiac hypertrophy in female murine hearts , 2016, Experimental physiology.
[3] Stefan R Bornstein,et al. Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline. , 2016, The Journal of clinical endocrinology and metabolism.
[4] Jin Han,et al. Influence of starvation on heart contractility and corticosterone level in rats , 2015, Pflügers Archiv - European Journal of Physiology.
[5] S. Tipparaju,et al. High level of oxygen treatment causes cardiotoxicity with arrhythmias and redox modulation. , 2015, Toxicology and applied pharmacology.
[6] M. Quick,et al. Potentiation of the Kv1 family K(+) channel by cortisone analogues. , 2012, ACS chemical biology.
[7] Martina Sauert,et al. Polyol pathway impairs the function of SERCA and RyR in ischemic-reperfused rat hearts by increasing oxidative modifications of these proteins. , 2010, Journal of molecular and cellular cardiology.
[8] O. Pongs,et al. Ancillary subunits associated with voltage-dependent K+ channels. , 2010, Physiological reviews.
[9] M. Breschi,et al. Anti‐ischaemic activity of an antioxidant aldose reductase inhibitor on diabetic and non‐diabetic rat hearts , 2010, The Journal of pharmacy and pharmacology.
[10] D. Mukherjee,et al. Excess of Glucocorticoid Induces Cardiac Dysfunction via Activating Angiotensin II Pathway , 2009, Cellular Physiology and Biochemistry.
[11] V. Kabaleeswaran,et al. Cortisone dissociates the Shaker family K+ channels from their beta subunits. , 2008, Nature Chemical Biology.
[12] A. Bhatnagar,et al. Catalytic mechanism and substrate specificity of the beta-subunit of the voltage-gated potassium channel. , 2008, Biochemistry.
[13] M. A. Ramirez,et al. Epalrestat: An Aldose Reductase Inhibitor for the Treatment of Diabetic Neuropathy , 2008, Pharmacotherapy.
[14] A. Bhatnagar,et al. NADPH binding to beta-subunit regulates inactivation of voltage-gated K(+) channels. , 2007, Biochemical and biophysical research communications.
[15] R. Kumar,et al. Differential regulation of voltage-gated K+ channels by oxidized and reduced pyridine nucleotide coenzymes. , 2005, American journal of physiology. Cell physiology.
[16] N. Narayanan,et al. Dexamethasone treatment improves sarcoplasmic reticulum function and contractile performance in aged myocardium , 2004, Molecular and Cellular Biochemistry.
[17] Brian F. Johnson,et al. Cardiac abnormalities in diabetic patients with neuropathy: effects of aldose reductase inhibitor administration. , 2004, Diabetes care.
[18] A. Zacarias,et al. Binding of Pyridine Nucleotide Coenzymes to the β-Subunit of the Voltage-sensitive K+ Channel* , 2001, The Journal of Biological Chemistry.
[19] J. Starkopf,et al. Pretreatment with methylprednisolone protects the isolated rat heart against ischaemic and oxidative damage , 2000, Free radical research.
[20] J. Hancox,et al. An investigation of the role played by the E-4031-sensitive (rapid delayed rectifier) potassium current in isolated rabbit atrioventricular nodal and ventricular myocytes , 1999, Pflügers Archiv.
[21] N. Hotta,et al. Effects of an aldose reductase inhibitor, epalrestat, on diabetic neuropathy. Clinical benefit and indication for the drug assessed from the results of a placebo-controlled double-blind study. , 1995, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.